ELDN Stock Summary and Trading Ideas (Eledon Pharmaceuticals | NASDAQ:ELDN)

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Eledon Pharmaceuticals trades on the NASDAQ stock market under the symbol ELDN.

As of March 3, 2025, ELDN stock price declined to $4.12 with 26,444 million shares trading.

ELDN has a beta of 0.76, meaning it tends to be less sensitive to market movements. ELDN has a correlation of 0.01 to the broad based SPY ETF.

ELDN has a market cap of $246.13 million. This is considered a Small Cap stock.

In the last 3 years, ELDN traded as high as $5.54 and as low as $1.07.

The top ETF exchange traded funds that ELDN belongs to (by Net Assets): VTI, VXF, FDLS, IWC, SBIO.

ELDN has outperformed the market in the last year with a return of +123.9%, while the SPY ETF gained +18.4%. However, in the most recent history, ELDN shares have underperformed the stock market with its stock returning -3.3% in the last 3 month period and -9.1% for the last 2 week period, while SPY has returned -0.7% and -2.8%, respectively.

ELDN support price is $3.99 and resistance is $4.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELDN shares will trade within this expected range on the day.